- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Summer 2015
| Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
|---|---|---|---|---|---|
| Exforge | Novartis | Amlodipine / Valsartan | Lupin Pharmaceuticals | treatment of hypertension and to lower blood pressure | 4/1/2015 |
| FemHRT | Warner Chilcott | Norethindrone Acetate / Ethinyl Estradiol | Glenmark Generics | moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis in women at significant risk of osteoporosis | 4/7/2015 |
| Generess Fe Tablets | Warner Chilcott | Norethindrone / Ethinyl Estradiol / Ferrous Fumarate | Mylan | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 4/7/2015 |
| Exalgo | Mallinckrodt | Hydromorphone Extended-Release Tablets | Perrigo | treatment of chronic pain in opioid-tolerant patients requiring continuous around-the-clock opioid analgesia for an extended amount of time | 4/8/2015 |
| Lybrel | Wyeth | Levonorgestrel / Ethinyl Estradiol Tablets USP | Glenmark Generics | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 4/10/2015 |
| Kenalog Topical Spray | Sun Pharma | Triamcinolone Acetonide Topical Aerosol | Perrigo | relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses | 4/16/2015 |
| Abilify | Otsuka Pharmaceutical | Aripiprazole | Teva Pharmaceutical Industries | treatment of schizophrenia and for the acute treatment of manic and mixed episodes associated with bipolar I disorder | 4/28/2015 |
| Seasonale | Teva Women's Health | Levonorgestrel / Ethinyl Estradiol Tablets | Mylan | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 5/5/2015 |
| Pulmicort Respules | AstraZeneca | Budesonide Inhalation Suspension | Allergan | maintenance medicine to control and prevent asthma symptoms in children ages 12 months to 8 years | 5/7/2015 |
| Lotronex | Prometheus Laboratories | Alosetron Hydrochloride Tablets | Roxane Laboratories | for some women with severe Irritable Bowel Syndrome (IBS) | 5/21/2015 |
| DDAVP | Ferring Pharmaceuticals | Desmopressin Acetate Tablets | Glenmark Pharmaceuticals | antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region | 5/29/2015 |
| Lomedia 24 Fe | Amneal | Norethindrone Acetate / Ethinyl Estradiol / Ferrous Fumarate | Teva | for prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 5/29/2015 |
| Actonel | Actavis | Risedronate Sodium Tablets | Teva | help increase bone mass and help reduce the chance of having a spinal or non-spinal fracture (break) and are also used to treat or prevent osteoporosis in either men or women who are taking corticosteroid medicines, and to treat Paget's disease of the bone | 6/1/2015 |
| Intuniv | Shire | Guanfacine Hydrochloride Extended-Release Tablets | Mylan | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 6/2/2015 |
| Seasonique | Teva | Levonorgestrel / Ethinyl Estradiol Tablets | Mylan (Famy Care) | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 6/2/2015 |
| Intuniv | Shire | Guanfacine Hydrochloride Extended-Release Tablets | Teva | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 6/2/2015 |
| Intuniv | Shire | Guanfacine Hydrochloride Extended-Release Tablets | Sandoz | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 6/4/2015 |
| Dovonex Cream | Leo Pharma | Calcipotriene Cream | Glenmark Pharmaceuticals | treatment for psoriasis | 6/11/2015 |
| Seasonale | Teva Women's Health | Levonorgestrel / Ethinyl Estradiol Tablets | Glenmark Pharmaceuticals | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 6/15/2015 |
| Copaxone | Teva | Glatiramer Acetate | Sandoz | treatment for relapsing forms of Multiple Sclerosis | 6/18/2015 |
GENERICally Speaking Summer 2015
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.